Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377805 | 1.00 | CHRM3 (0.42) | CHRM3L3MBTL1TDP1CA1CA2 | |
| SCHEMBL13377795 | 0.89 | CA1 (0.41) | CHRM3L3MBTL1TDP1CA1CA2 | |
| SCHEMBL13377618 | 0.87 | L3MBTL1 (0.41) | CHRM3L3MBTL1TDP1SLC6A1SLC6A11 | |
| SCHEMBL2769219 | 0.85 | L3MBTL1 (0.40) | CHRM3L3MBTL1TDP1CA1CA2 | |
| SCHEMBL2769924 | 0.85 | L3MBTL1 (0.42) | CHRM3L3MBTL1TDP1CA1CA2 | |
| SCHEMBL2771845 | 0.83 | CA1 (0.48) | CHRM3L3MBTL1TDP1CA1CA2 | |
| SCHEMBL24763738 | 0.81 | CHRM3 (0.41) | CHRM3L3MBTL1TDP1SLC6A1SLC6A11 | |
| SCHEMBL4184119 | 0.81 | NAAA (0.38) | CHRM3CA1CA2 | |
| SCHEMBL4184115 | 0.81 | NAAA (0.38) | CHRM3CA1CA2 | |
| SCHEMBL4192567 | 0.80 | DUT (0.39) | CHRM3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683164-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | BIO-RAD LABORATORIES INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | POLRMT, NSUN2, RNGTT | CHRM3 3806/4885L3MBTL1 117/4885TDP1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.